Espero Biopharma, Inc.
Records under this name other than patents Espero Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Espero Biopharma, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,498,449 | Antiarrhythmic Precursor Compounds, Methods of Synthesis and Methods of Use now held by Xyra, LLC In force · High confidence | In force | High confidence | |
| US 9,549,912 | Methods for Treating Atrial Fibrillation now held by Xyra, LLC In force (reinstated) · Medium confidence | In force (reinstated) | Medium confidence | |
| US 7,105,568 | Novel Compounds for Treatment of Cardiac Arrhythmia and Methods of Use now held by Hesp LLC Term ended Term ended Apr 8, 2025 · High confidence | Term ended | Term ended Apr 8, 2025 | High confidence |
| US 6,869,972 | Novel Compounds for Treatment of Cardiac Arrhythmia, Synthesis, and Methods of Use now held by Hesp LLC Term ended Term ended Dec 10, 2022 · High confidence | Term ended | Term ended Dec 10, 2022 | High confidence |
| US 7,037,933 | Novel Compounds for Treatment of Cardiac Arrhythmia, Synthesis, and Methods of Use now held by Hesp LLC Term ended Term ended Dec 10, 2022 · Medium confidence | Term ended | Term ended Dec 10, 2022 | Medium confidence |
| US 7,145,020 | Materials and Methods for Treating Coagulation Disorders now held by Cadrenal Therapeutics Term ended Ended no later than Apr 24, 2022 · Low confidence | Term ended | Ended no later than Apr 24, 2022 | Low confidence |
| US 7,253,208 | Materials and Methods for Treating Coagulation Disorders now held by Cadrenal Therapeutics Term ended Ended no later than Apr 24, 2022 · Low confidence | Term ended | Ended no later than Apr 24, 2022 | Low confidence |
| US 7,285,671 | Materials and Methods for Treating Coagulation Disorders now held by Cadrenal Therapeutics Term ended Ended no later than Apr 24, 2022 · Low confidence | Term ended | Ended no later than Apr 24, 2022 | Low confidence |
| US 7,666,902 | Haloalkyl Ester Derivatives of Coumarin for the Treatment of Coagulation Disorders now held by Cadrenal Therapeutics Term ended Term ended Apr 24, 2022 · Medium confidence | Term ended | Term ended Apr 24, 2022 | Medium confidence |
| US 7,932,405 | Halogenated Ester Derivatives of Coumarins for the Treatment of Coagulation Disorders now held by Cadrenal Therapeutics Term ended Term ended Apr 24, 2022 · Medium confidence | Term ended | Term ended Apr 24, 2022 | Medium confidence |